设计,合成和研究基于基的新型抗瘤脂,降低p38基激活蛋白激酶的调节
Ahmed H E Hassan1,2, Yeon Il Oh3, Chae Hyeon Lee4
1Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Journal of enzyme inhibition and medicinal chemistry
|May 29, 2023
概括
基于基的新型EDELFOSINE类似物通过抑制p38 MAPK.表现出强大的抗癌活性. 化合物1b和1a是有希望的广谱抗瘤脂质,需要进一步开发.
科学领域:
- 药用化学 医学化学
- 分子药理学分子药理学
- 癌症生物学 癌症生物学
背景情况:
- 埃德尔福辛类似物正在研究抗瘤特性.
- p38 MAPK是癌症的一个关键信号通路.
- 开发新的基于脂质的抗癌药物至关重要.
研究的目的:
- 设计和合成基于基的新型EDELFOSINE类似物.
- 为了评估它们对不同癌症细胞系的抗瘤活性.
- 研究它们的作用机制,重点关注p38 MAPK调制.
主要方法:
- 合成基于基的埃德尔福辛类似物,使用不同的基替代剂.
- 对九个癌细胞面板进行抗癌活性查.
- 对p38 MAPK和AKT通路的抑制试验.
- 在基分子对接研究中.
主要成果:
- 和和单不和的基替代衍生品显示了最高的活性.
- 整形替代化合物比元替代或副替代化合物更强效.
- 化合物1b和1a对血液,肺,结肠,中枢神经系统,卵巢,脏和前列腺癌具有广泛的抗癌活性.
- 化合物1b选择性抑制了p38 MAPK,而不是AKT.
- 在学研究表明,1b和1a与p38 MAPK的脂质结合口袋结合.
结论:
- 化合物1b和1a是强大的,广泛的抗瘤脂质.
- 它们通过调节p38 MAPK活动来起作用.
- 这些化合物代表了进一步抗癌药物开发的有希望的候选人.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
相关概念视频
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
01:07MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K